Start for free
Start for free
BV

Birk Venture

Europe, Oslo, Norway, Oslo

Description

Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.

Investor Profile

Birk Venture has made 9 investments, with 0 in the past 12 months and 22% as lead.

Stage Focus

  • Seed (56%)
  • Series A (22%)
  • Series Unknown (22%)

Country Focus

  • Norway (78%)
  • United Kingdom (22%)

Industry Focus

  • Biotechnology
  • Medical
  • Health Care
  • Pharmaceutical
  • Biopharma
  • Finance
  • Therapeutics
  • Venture Capital
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Birk Venture frequently co-invest with?

TeleVenture Management
TeleVenture Management
Europe, Oslo, Norway, Oslo
Co-Investments: 1
Sarsia Seed Management
Sarsia Seed Management
Europe, Hordaland, Norway, Bergen
Co-Investments: 3
iGlobe Partners
iGlobe Partners
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
Primavera Capital Group
Primavera Capital Group
Asia, Beijing, China, Beijing
Co-Investments: 2

What are some of recent deals done by Birk Venture?

Accession Therapeutics

Oxford, Oxfordshire, United Kingdom

Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity.

BiopharmaBiotechnology
Series ANov 21, 2022
Amount Raised: $19,631,913
Accession Therapeutics

Oxford, Oxfordshire, United Kingdom

Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity.

BiopharmaBiotechnology
SeedSep 20, 2021
Amount Raised: $15,028,308
Zelluna Immunotherapy

Oslo, Oslo, Norway

Zelluna Immunotherapy is a privately owned Norwegian biopharmaceutical company.

BiotechnologyHealth CareMedicalPharmaceutical
SeedJan 1, 2017
APIM Therapeutics

Trondheim, Sor-Trondelag, Norway

APIM Therapeutics is developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen).

BiotechnologyFinanceTherapeuticsVenture Capital
Series UnknownOct 17, 2012
Circio

Oslo, Oslo, Norway

Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.

BiotechnologyHealth CareMedical
Series AFeb 1, 2012
Amount Raised: $2,238,256
APIM Therapeutics

Trondheim, Sor-Trondelag, Norway

APIM Therapeutics is developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen).

BiotechnologyFinanceTherapeuticsVenture Capital
Series UnknownNov 10, 2011
BerGenBio

Bergen, Hordaland, Norway

BerGenBio is clinical-stage biopharma developing first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.

BiotechnologyPharmaceutical
SeedMar 2, 2011
Amount Raised: $1,300,000
Nordic Nanovector

Oslo, Oslo, Norway

Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers.

BiotechnologyLife ScienceMedical
SeedJan 1, 2010
Nextera

Oslo, Oslo, Norway

Nextera offers a highly versatile and innovative platform that finds its application in a broad array of fields.

BiotechnologyHealth CareMedicalPharmaceutical
SeedJan 1, 2010
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator